<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564340</url>
  </required_header>
  <id_info>
    <org_study_id>R4018-ONC-1721</org_study_id>
    <secondary_id>2019-003298-24</secondary_id>
    <nct_id>NCT03564340</nct_id>
  </id_info>
  <brief_title>Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer</brief_title>
  <official_title>A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the Dose Escalation Phase are to assess the safety and
      pharmacokinetics (PK) in order to determine a maximally tolerated dose (MTD) or recommended
      phase 2 dose (RP2D) of REGN4018 as monotherapy and in combination with cemiplimab. In the
      Dose Expansion Phase, the primary objectives are to assess the preliminary efficacy of
      REGN4018 as monotherapy and in combination with cemiplimab, (separately by cohort) as
      determined by the objective response rate (ORR) by Response Evaluation Criteria in Solid
      Tumors (RECIST) 1.1.

      The secondary objectives of the Dose Escalation Phase are to assess the preliminary efficacy
      of REGN4018 as monotherapy and in combination with cemiplimab (separately by cohort) as
      determined by ORR by RECIST 1.1. In the Dose Expansion Phase, the secondary objectives are to
      characterize the safety profile in each expansion cohort and characterize the PK of REGN4018
      as monotherapy and in combination with cemiplimab. In both the Dose Escalation and Dose
      Expansion Phases, secondary objectives are to assess preliminary efficacy of REGN4018 as
      monotherapy and in combination with cemiplimab (separately by cohort) as measured by ORR
      based on immune based therapy RECIST (iRECIST), best overall response (BOR), duration of
      response (DOR), disease control rate, and progression-free survival (PFS) based on RECIST 1.1
      and iRECIST, to assess efficacy of REGN4018 as monotherapy and in combination with cemiplimab
      as measured by CA-125 level and immunogenicity of REGN4018 and cemiplimab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Anticipated">March 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting toxicity (DLTs) for REGN4018 monotherapy</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with DLTs for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (irAEs)) for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with TEAEs (including irAEs) for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with serious adverse events (SAEs) for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with SAEs for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of deaths for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of deaths for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of REGN4018 in serum over time for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of REGN4018 in serum over time for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Eisenhauer 2009) for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR defined by RECIST 1.1 for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR based on RECIST 1.1 (Eisenhauer 2009) for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR based on RECIST 1.1 for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with TEAEs (including irAEs) for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with TEAEs (including irAEs) for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with SAEs for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with SAEs for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of REGN4018 in serum over time for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of REGN4018 in serum over time for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Expansion Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR based on iRECIST (Seymour 2017) for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR based on iRECIST for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR) based on RECIST 1.1 for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOR based on iRECIST for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOR based on RECIST 1.1 for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOR based on iRECIST for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) based on RECIST 1.1 for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR based on iRECIST for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR based on RECIST 1.1 for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR based on iRECIST for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate based on RECIST 1.1 for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate based on iRECIST for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate based on RECIST 1.1 for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate based on iRECIST for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) based on RECIST 1.1 for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS based on iRECIST for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS based on RECIST 1.1 for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS based on iRECIST for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer antigen-125 (CA-125) response for REGN4018 monotherapy</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 response for REGN4018 with cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of anti-drug antibodies against REGN4018</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of anti-drug antibodies against cemiplimab</measure>
    <time_frame>Up to 62 weeks</time_frame>
    <description>Dose Escalation and Dose Expansion Phases</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Recurrent Ovarian Cancer</condition>
  <condition>Recurrent Fallopian Tube Cancer</condition>
  <condition>Recurrent Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN4018 administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN4018 and cemiplimab administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN4018</intervention_name>
    <description>REGN4018 will be administered in a series of dose escalation cohorts by a weekly intravenous (IV) infusion during 6-week cycle (42 days).</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cemiplimab</intervention_name>
    <description>Cemiplimab will be administered in a series of dose escalation cohorts by IV infusion every 3 weeks over 6 week cycles.</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>REGN2810</other_name>
    <other_name>Libtayo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed diagnosis of advanced,
             epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian
             tube cancer who have all of the following:

          -  serum CA-125 level â‰¥2x upper limit of normal (ULN) (in screening)

          -  has received at least 1 line of platinum-containing therapy or must be
             platinum-intolerant

          -  documented relapse or progression on or after the most recent line of therapy

          -  no standard therapy options likely to convey clinical benefit

          -  Adequate organ and bone marrow function as defined in the protocol

          -  Adequately controlled blood pressure

          -  Life expectancy of at least 3 months

        Key Exclusion Criteria:

          -  Recent treatment with anti-Programmed Cell Death (PD-1)/PD-L1 therapy

          -  Expansion cohort only: More than 3 prior lines of cytotoxic chemotherapy for
             platinum-experienced and/or intolerant disease

          -  Expansion cohort only: prior treatment with a Mucin 16 (MUC16)-targeted therapy

          -  Untreated or active primary brain tumor, central nervous system (CNS) metastases, or
             spinal cord compression

          -  History of clinically significant cardiac disease, myocarditis, presence of moderate
             to large pericardial effusion and other measures of cardiac health as defined in the
             protocol

          -  Moderate to large pleural effusion as defined in the protocol

        Note: Other protocol Inclusion/Exclusion Criteria apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trails Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Hilliard</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

